PN-943
Protagonist Therapeutics, Inc.
[]
#walterreinisch pii rct to evaluate safety&amp;efficacy of oral, gut-restricted 4 7 integrin peptide antagonist pn-943 in uc: #uegweek22 - primary endpoint not met
- pn-943 at 150 mg bid, but not 450 mg bid, demonstrated concordant treatment effects across sec endpoints 
Professor of Medicine, Gastroenterologist, specializing in the care of patients with IBD.
National representative of Germany @ https://t.co/Qr0PthTmU8 ex @Y_ECCO_IBD chair